Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer
Cancer Chemotherapy and Pharmacology, 07/17/2012
Sym SJ et al. – The recommended dose (RD) of the epirubicin, oxaliplatin, and S–1 (EOS) regimen in patients with previously untreated advanced gastric cancer (AGC) was 50mg/m2 of epirubicin and 130mg/m2 of oxaliplatin on day 1, with administration of 40mg/m2 of S–1 twice a day on days 1–14 for each 21–day cycle. The EOS regimen described produced promising results.
